COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy.

Journal Article (Letter)

• COVID-19 patients are at increased risk of thromboembolic complications. • Escalated-dose thromboprophylaxis may help reduce the rate of thromboembolic events. • The bleeding risk is highest for patients treated with therapeutic anticoagulation.

Full Text

Duke Authors

Cited Authors

  • Daughety, MM; Morgan, A; Frost, E; Kao, C; Hwang, J; Tobin, R; Patel, B; Fuller, M; Welsby, I; Ortel, TL

Published Date

  • December 2020

Published In

Volume / Issue

  • 196 /

Start / End Page

  • 483 - 485

PubMed ID

  • 33091700

Pubmed Central ID

  • PMC7557260

Electronic International Standard Serial Number (EISSN)

  • 1879-2472

Digital Object Identifier (DOI)

  • 10.1016/j.thromres.2020.10.004


  • eng

Conference Location

  • United States